Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication.
Blum
M W
MW
Department of Clinical Pharmacology and Toxicology, University Hospital, Zürich, Switzerland.
Siegel
A M
AM
Meier
R
R
Hess
K
K
D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001577:Benzophenones / Q000008:administration & dosage / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology*; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology*; D009460:Neurologic Examination / Q000187:drug effects; D009596:Nitrophenols; D000077867:Tolcapone
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D001577:Benzophenones; D009596:Nitrophenols; D000077867:Tolcapone; D003024:Clozapine